Gewinn- und Verlust:

Crocs (CROX) is experiencing a significant rise due to a strong holiday quarter performance and optimistic FY26 guidance. The company reported a substantial Q4

VANCOUVER, BC - TheNewswire - January 3, 2026 – Rush Gold Corp. (the “ Company ” or “ Rush ”) (CSE: RGN; FSE: B6H; OTCQB: RGNCF) is pleased to announce that its common shares have commenced trading on the OTCQB® Venture Market in the United States under the symbol “RGNCF”. Rush's common shares will continue to trade on the Canadian Securities Exchange under the symbol “RGN”. The Company has also secured eligibility for its common shares to settle electronically via the Depository Trust Company (“ DTC ”), enabling smoother, more cost-effective transactions through the U.S. clearing system.   The OTCQB is recognized by the U.S. Securities and Exchange Commission as an “established public market” and is designed for U.S. and international companies in the entrepreneurial and development stage. The listing is expected to increase the Company's visibility among U.S. investors, improve trading accessibility, and enhance overall liquidity.

Deckers Outdoor (DECK) reported exceptional third-quarter results, surpassing EPS and revenue expectations, and raised its FY26 outlook beyond analyst predictio

Revenue: $1.96 billion, a 7% increase versus the prior year.HOKA Revenue: $629 million, an 18% increase versus last year.UGG Revenue: $1.3 billion, a 5% increa

Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program. Defence has been collaborating with CNL on the development of an Accum®-enhanced radio-immunoconjugate program.

Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company, today announced an evolution of its corporate positioning to reflect its focus as a precision intracellular drug-delivery company advancing its proprietary Accum® platform through both internal development programs and strategic partnerships. Designed to unlock the full potential of complex cancer biologics, Accum® enhances intracellular delivery to increase therapeutic potency while reducing toxicity.

Nike (NKE) exceeded expectations in its Q2 results, delivering both top and bottom-line growth. Despite this, a cautious outlook for the holiday quarter and ong

Nike Inc (NYSE:NKE, XETRA:NKE) will report its fiscal second quarter results on December 18, with UBS analysts expecting a relatively muted reaction from Wall Street despite signs of uneven momentum across the athletic footwear and apparel brand's key markets. The firm repeated its ‘Neutral' rating and a $71 price target, writing that they “don't expect Nike's print to change Street estimates or the stock's price-to-earnings ratio (P/E) much.

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2025) - Metalsource Mining, Inc. (CSE: MSM) (FSE: E9Z) (OTCQB: SFRIF) ("Metalsource" or the "Company"), is pleased to announce that its common shares have been made eligible for electronic clearing and settlement through the Depository Trust Company (DTC) in the United States. DTC eligibility streamlines the process of trading the Company's shares, allowing for faster settlement, simplified electronic transfers, and broader access to U.S brokerage firms & investors.

Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board ("SAB"), composed of Rob Leanna, Danny Chui, and Brendan Hussey. Defence's Accum®-Antibody drug conjugate ("ADC") program has reached laboratory validations, demonstrating a significant increase in intracellular accumulation and improved efficacy for Accum®-enhanced ADCs.